tbuckley/cabot-search huggingface dataset:
A retrospective study on the role of endoscopic ultrasonography in preoperative staging of rectal cancer
Authors: Xu Guoliang, Lin Shiyong, Luo Guangyu, Shan Hongbo, Gao Xiaoyan, Li Yin, Zhang Rong, Li Jianjun, He Longjun, Wang Guobao
Journal: Endoscopy (2011)

Aim: The aim of the present study was to evaluate the application of endoscopic ultrasonography for the preoperative staging of rectal cancer in our own experience. Patients and Methods: Between April 2004 and May 2010, all patients with rectal cancer and without neoadjuvant therapy underwent endoscopic ultrasonography, followed by operation at our hospital. The results of endoscopic ultrasonographic staging were compared with those of the postoperative histopathological staging. Results: The accuracy of overall T staging was 86.5%, and for T1, T2, T3 and T4, it was 86.7%, 94.0%, 86.2%, and 65.5%, respectively. The accuracy of T staging for ulcerated lesions was significantly lower than that of non-ulcerated ones. There was also significant difference of the accuracy for T staging between the lesions with a nontraversable stenosis and those without a stricture. The accuracy of N staging was 77.8%, with the specificity and sensitivity being 85.6% and 74.2%, respectively. Conclusions: Endoscopic ultrasonography is safe and effective for preoperative staging of rectal cancer. But as for ulcerated lesions and cases with nontraversable stenoses, the results of EUS staging could be doubtful.
Increased Expression of the Epithelial Anion Transporter Pendrin in Nasal Polyp Tissues of Patients with Chronic Rhinosinusitis
Authors: Sudarshan Seshadri, Xiang Lu, Andrew Choi, Roderick Carter, James Norton, Atsushi Kato, Lydia Suh, Anju Peters, David Conley, Rakesh Chandra, Bruce Tan, Leslie C. Grammer, Robert Kern, Robert P. Schleimer
Journal: Journal of Allergy and Clinical Immunology (2013)
Abstract 5106: A HHIP derived gene expression signature for the prediction of patient survival after adjuvant chemotherapy of pancreatic cancer
Authors: Christian Pilarsky, Tobias Gorille, Felix Rückert, Robert Grützmann, Hans Detlev Saeger
Journal: Cancer Research (2012)

Abstract Prognosis for patients with pancreatic carcinoma (PDAC) remains poor. Despite of increasing knowledge about the molecular basis of PDAC neither a specific marker for early diagnosis nor target proteins for a new therapeutic approach have been identified so far. However, reliable prediction of survival might help to improve the therapeutic outcome for patients with PDAC. In recent years it has become evident, that the Hedgehog (Hh) signal transduction pathway is a key regulator of pancreatic cancer development. Hedgehog interacting protein (HHIP) is a key modulator of Hh action and is overexpressed in the tumor stroma of PDACs. Reasoning that HHIP could serve as an indicator of Hh signaling activation we identified HHIP associated genes (HAG) using guilt by association (GBA) analysis in a set of PDAC gene expression profiles from microdissected tissue. Using the Affymetrix GeneChip U133 2.0 array and TNASAS we analyzed the gene expression profile of 59 PDAC samples and identified prognostic marker from HAG for survival of PDAC patients with adjuvant therapy. GBA analysis of gene expression profiles from microdissected PDAC tissue yielded 276 HAGs. TNASAS analysis using these genes revealed a prognostic gene expression signature of 50 genes, which was able to identify patients receiving adjuvant therapy with gemcitabine surviving more than 24 month with a total error of 0.087. TNASAS analysis of samples from patients treated without adjuvant therapy failed to identify a gene set with prognostic significance. Gene expression analysis is able to identify genes with prognostic significance in patients with adjuvant chemotherapy. These genes seem to be correlated with the efficacy of adjuvant gemcitabine therapy. Further analysis of those genes can reveal more insights in the signal transduction mechanisms associated with those genes. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5106. doi:1538-7445.AM2012-5106
Abstract 5101: Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics
Authors: Thomas Wiedl, Stephan Arni, Bernd Roschitzki, Jonas Grossmann, Alex Soltermann, Sven Hillinger, Rudolf Aebersold, Walter Weder
Journal: Cancer Research (2011)

Abstract Background: Lung cancer is the leading cause of all cancer related deaths and treatment is still suboptimal. Novel biomarkers with a reliable predictive significance which may additionally represent therapeutic targets are therefore of utmost importance. In biomarker discovery studies transcript or protein abundances are typically compared in normal versus disease states. However, crucial changes in enzymatic activities remain undetected. Based on the work of Prof. Cravatt and others, activity-based proteomics has become a promising option to circumvent this limitation. This study aims to establish a robust and high throughput activity-based proteomics platform and to investigate the role of serine hydrolase activity profiles as prognostic biomarkers in lung cancer. Methods: A fluorophosphate derivate (CAS-Number: 353754-93-5) was used to covalently target serine hydrolases in proteomes derived from human lung adenocarcinoma biopsies and corresponding normal lung tissues (tumor cell content: &amp;gt;50%, TNM-stage: I-IV). Tagged proteins were subsequently affinity purified and analyzed using a directed mass spectrometry based approach (LTQ-FTMS, Thermo Finnigan). Data were qualitatively analyzed using the Mascot 2.2 search engine and Progenesis LC-MS version 2.5 (Nonlinear Dynamics) was employed for relative quantification. Results: The strategy described above results in the simultaneous qualitative and quantitative analysis of serine hydrolase activities in complex proteomes, thereby representing a valid alternative to activity-based proteomics approaches described so far. The analysis of 40 pairs of fresh frozen malignant and corresponding normal lung tissues in combination with clinical follow-up data led to the identification of two biomarker candidates that have previously not been associated with lung cancer. Conclusion &amp; Outlook: Based on the results obtained in this study we conclude that activity-based proteomics represents a powerful strategy in the seek for novel biomarker candidates in human lung adenocarcinoma. Future research will involve data validation with additional samples from our tumor bank using advanced quantitative Multiple Reaction Monitoring (MRM) technology. Liu, Y., Patricelli, M.P. &amp; Cravatt, B.F. Activity-based protein profiling: the serine hydrolases. Proceedings of the National Academy of Sciences of the United States of America 96, 14694-14699 (1999). Jessani, N., et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nature methods 2, 691-697 (2005). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5101. doi:10.1158/1538-7445.AM2011-5101
THU0377 Frequency of Antibodies for Diagnosis of Coeliac Disease in Patients with Connective Tissue Diseases and Inflammatory Arthopathies: Table 1.
Authors: G.R. Rodriguez, F. Zazzetti, S. da Representaçao, M.V. Lencina, J.C. Barreira
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Coeliac disease (CD) is an autoimmune disease caused by exposure to gluten in genetically predisposed individuals. The detection of anti-transglutaminase IgA (tTG) and anti-endomysial (EMA) is used for screening of CD with sensitivity and specificity of 90% and 99%. The association between CD and connective tissue diseases (CTD) has been reported. <h3>Objectives</h3> The objective was to describe the frequency of IgA tTG and EMA in patients with definite diagnosis of CTD and inflammatory arthropathies (IA). <h3>Methods</h3> Patients ≥18 years with CTD and IA were included. Values of ≥20 for tTG (ELISA) and ≥10 for EMA (IIF) were considered positive. Medium were used for numeric variables and interquartile percentages for categorical variables. Confidence intervals were calculated for 95%. <h3>Results</h3> Of 149 patients with various diagnoses included, 8 had at least one positive antibody (5.37% CI =1.75-8.99), 6 had both (4.03% CI =0.87-7,18) and 2 had only tTG. Eight patients were diagnosed with CD and biopsy was performed in 4 (see table below). In this study 5.37% presented positive serology for CD. Positive antibodies were found in patients with Sjögren9s syndrome, rheumatoid arthritis, psoriatic arthritis, polymyositis and lupus, as reported by other authors. <h3>Conclusions</h3> According to our findings, it would be useful to perform a serological screening for CD in CTD, due to the overlap of autoimmune diseases, as well as in undifferentiated arthritis, to determine in those patients in whom the small bowel biopsy should be performed for definitive diagnosis. <h3>References</h3> Gόmez JC, Selvaggio GS, Viola M, Pizarro B, La Motta G, de Barrio S et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. Am J Gastroenterol 2001; 96: 2700-4. Luft LM, Barr SG, Martin LO, Chan EK, Fritzler MJ. Autoantibodies to tissue transglutaminase in Sjögren9s syndrome and related rheumatic diseases. J Rheumatol 2003; 30:2613-9. Koehne Vde B, Bahia M, Lanna CC, Pinto MR, Bambirra EA, Cunha AS. Prevalence of serological markers for celiac disease (IgA and IgG class antigliadin antibodies and IgA class antiendomysium antibodies) in patients with autoimmune rheumatologic diseases in Belo Horizonte, MG, Brazil.Arq Gastroenterol; 2010; 47:250-6. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2624
EFFECT OF BALLOON PULMONARY ANGIOPLASTY FOR INOPERABLE PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN WHOM MEAN PULMONARY ARTERIAL PRESSURE WAS LESS THAN 30MMHG
Authors: Hideya Shigyo, Akihiro Tsuji, Jin Ueda, Shigefumi Fukui, Takeshi Ogo, Yoshihiro Sanda, Yoshiaki Morita, Tetsuya Fukuda, Satoshi Yasuda, Hisao Ogawa, Norifumi Nakanishi
Journal: Journal of the American College of Cardiology (2015)
Endoscopic findings in Cowden syndrome
Authors: R. Coriat, M. Mozer, E. Caux, A. Chryssostalis, B. Terris, S. Grandjouan, R. Benamouzig, A. Martin, S. Chaussade
Journal: Endoscopy (2011)

Corrected by: Endoscopic findings in Cowden syndromeEndoscopy 2011; 43(12): 1096-1096DOI: 10.1055/s-0030-1257072
A Controlled Trial of Exercise Rehabilitation after Heart Transplantation
Authors: Jon A. Kobashigawa, David A. Leaf, Nancy Lee, Michael P. Gleeson, HongHu Liu, Michele A. Hamilton, Jaime D. Moriguchi, Nobuyuki Kawata, Kim Einhorn, Elise Herlihy, Hillel Laks
Journal: New England Journal of Medicine (1999)

In patients who have received a cardiac transplant, the denervated donor heart responds abnormally to exercise and exercise tolerance is reduced. The role of physical exercise in the treatment of patients who have undergone cardiac transplantation has not been determined. We assessed the effects of training on the capacity for exercise early after cardiac transplantation.
Early Computed Tomography Compared With Bone Scintigraphy in Suspected Scaphoid Fractures
Authors: Steven J. Rhemrev, Andele D. de Zwart, Lucas M. Kingma, Sven A. G. Meylaerts, Jan-Willem Arndt, Inger B. Schipper, Frank J. P. Beeres
Journal: Clinical Nuclear Medicine (2010)

This study examined whether multidetector computed tomography (CT) is superior to bone scintigraphy for diagnosis of an occult scaphoid fracture.In a study period of 22 months, 100 consecutive patients with a clinically suspected scaphoid fracture and no fracture on scaphoid radiographs, were evaluated with CT within 24 hours after injury and bone scintigraphy between 3 and 5 days after injury. The reference standard for a true (radiographic occult) scaphoid fracture was either (1) diagnosis of fracture on both CT and bone scintigraphy or (2) in case of discrepancy, clinical and/or radiographic evidence of a fracture during follow-up.CT showed 10 scaphoid and 18 other fractures. Bone scintigraphy showed 21 scaphoid and 36 other fractures. According to the reference standard, there were 14 scaphoid fractures. CT had a sensitivity of 64%, specificity of 99%, accuracy of 94%, a positive predictive value of 90%, and a negative predictive value of 94%. Bone scintigraphy had a sensitivity of 93%, specificity of 91%, accuracy of 91%, a positive predictive value of 62%, and a negative predictive value of 99%.This study could not confirm that early CT imaging is superior to bone scintigraphy for suspected scaphoid fractures.
Extracellular vesicles: masters of intercellular communication and potential clinical interventions
Authors: Jonathan M. Pitt, Guido Kroemer, Laurence Zitvogel
Journal: Journal of Clinical Investigation (2016)

Intercellular signaling via extracellular vesicles (EVs) is an underappreciated modality of cell-cell crosstalk that enables cells to convey packages of complex instructions to specific recipient cells. EVs transmit these instructions through their cargoes of multiple proteins, nucleic acids, and specialized lipids, which are derived from their cells of origin and allow for combinatorial effects upon recipient cells. This Review series brings together the recent progress in our understanding of EV signaling in physiological and pathophysiological conditions, highlighting how certain EVs, particularly exosomes, can promote or regulate infections, host immune responses, development, and various diseases - notably cancer. Given the diverse nature of EVs and their abilities to profoundly modulate host cells, this series puts particular emphasis on the clinical applications of EVs as therapeutics and as diagnostic biomarkers.
Serum and Tissue Concentration of Vitamin B<sub>12</sub>in Certain Pathologic States
Authors: James A. Halsted, Jean Carroll, Shirley Rubert
Journal: New England Journal of Medicine (1959)

VITAMIN B12 is widely used in medical practice, numerous reports having appeared that bear testimony to its therapeutic efficacy in such widely divergent conditions as trigeminal neuralgia,1 herpes zoster,2 subnormal growth of children,3 hepatitis,4 certain skin diseases5 and various neuropathies other than combined-system disease.6 As a rule the amounts employed have been very large, usually 1000 microgm. given parenterally at frequent intervals. Since the favorable results have usually been based on the fact that the patients improved concomitantly with the administration of the vitamin it is difficult to assess the mechanism of action or rationale for its use. Three . . .
Abstract 627: Etp-47187 a novel potent and efficacious dual inhibitor of phosphoinositide-3-kinases and mTOR
Authors: Guido Kurz, Pilar Pizcueta, Rosario Rico, David Cebrián, Enara Aguirre, David Soilan, Miguel A. Ortega, Sonia Martinez, Obdulia Rabal, C Gustavo Saluste, Estela Casas, Patricia Villanueva, Ana B. Garcia, Maria I. Albarran, Patricia Alfonso, Ester Gonzalez, Milagros Lorenzo, Francisco Ramos, Irene Palacios, Antonio Cebria, Antonio Rodriguez, Beatriz Noya, Ana M. Garcia, Sonsoles Rodriguez, José I. Martin, Rosa Alvarez, Ana I. Hernandez, Antonio Salgado, Elena Cerdon, Jesus Fominaya, Teresa G. Granda, Ana Rodriguez Lopez, Joaquin Pastor, James R. Bischoff
Journal: Cancer Research (2011)

Abstract The phosphoinositide-3-kinase (PI3K) signaling pathway is activated in a variety of solid and non-solid tumors. In many instances this is due to either activating mutations in the catalytic subunit of PI3Kα, p110α, or inactivating mutations or deletions of the tumor suppressor PTEN. In addition, the PI3K pathway is activated by mutations in certain receptor tyrosine kinases as well as by mutation of the oncogene KRAS. All of these lesions lead to enhanced activity of both PI3K and mTOR. Hence there is great interest to discover inhibitors of PI3K and mTOR for the treatment for cancer. Following a rational design strategy, we identified the fused thiadiazole derivative ETP-47187 as a potent dual inhibitor of PI3Kα and mTOR Kis = 0.18 nM and 1.2 nM, respectively. ETP-47187 also inhibits three oncogenc mutants of p110α: p110α E542K Ki = 0.38 nM, p110α E545K Ki = 0.2 nM and p110α H1047R Ki = 0.29 nM as well as PI3Kβ, PI3KΔ and PI3Kγ Kis 2.7, 0.26 and 1.5 nM, respectively. The compound inhibits PI3K signaling in treated tumor cell lines; the EC50 for inhibition of the phosphorylation of Akt was 5 nM. ETP-47187 has a pharmacokinetic profile suitable for oral dosing in mice (%F = 73%, Cl = 0.11 L/hr/kg; Vds = 0.38 L/h/kg). Treatment of tumor bearing mice with the compound causes a dose dependent reduction in P-Akt levels in the tumor. Once a day treatment of mice bearing human tumor xenografts with ETP-47187 results in significant tumor growth delay and is well tolerated. In a mouse model of lung cancer induced by expression of an oncogenic mutant KRAS, treatment with ETP-47187 blocked tumor growth and lead to a significant PET response. These and combination data will be discussed. We believe ETP-47187 and compounds like it are suitable to propose for clinical development in cancer patients with activated PI3K signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 627. doi:10.1158/1538-7445.AM2011-627
Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic.
Authors: Elizabeth S. Gabitzsch, Michael A. Morse, H. Kim Lyerly, Frank Jones
Journal: Cancer Research (2013)

Abstract In this Phase 1/2a non-randomized study, 32 patients having advanced stage metastatic colorectal cancer (mCRC) were treated with a novel immunotherapeutic, ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)). The trial included increasing doses of the agent and was found to be safe and well-tolerated at all doses assessed. There were no dropouts or treatments stopped due to adverse effects. Specific anti-CEA immune responses were observed in the majority of patients after they were treated three times over 6 weeks by subcutaneous injections of ETBX-011. Long-term follow-up in some of the patients reveled that the CEA directed immune responses persisted for up to 6-9 months after treatment and median overall-survival was 11 months. These results demonstrate that in mCRC patients the ETBX-011 immunotherapeutic generated significant CMI responses to the tolerized tumor antigen CEA. mCRC patients treated with ETBX-11 may experience extension of life and we are preparing to initiate a randomized, multicenter Phase 2b trial to further evaluate the clinical benefit. Citation Format: Elizabeth S. Gabitzsch, Michael A. Morse, H. Kim Lyerly, Frank Jones. Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-164. doi:10.1158/1538-7445.AM2013-LB-164 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Metabolism-perfusion mismatch as assessed by PET varies with breast cancer phenotype and predicts response to neoadjuvant chemotherapy.
Authors: JM Specht, BF Kurland, LK Dunnwald, RK Doot, JR Gralow, GK Ellis, HM Linden, RB Livingston, EK Schubert, DA Mankoff
Journal: Cancer Research (2009)

Abstract Abstract #6005 Background: Kinetic analysis of FDG and water PET can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC). Previously, we found that high pre-therapy glucose tumor metabolism relative to perfusion was associated with poor tumor pathologic response, early relapse, and death in patients with locally advanced breast cancer (LABC) treated with NC. This analysis examines tumor metabolism and perfusion as a function of tumor phenotype. Material and Methods: Tumor phenotype, defined by immunohistochemistry (IHC), was determined in 51 patients undergoing NC between 1995 and 2005. Luminal tumors were defined as those expressing either estrogen receptor (ER) or progesterone receptor (PR). The triple-negative (TN) phenotype was defined as ER and PR negative without HER2 overexpression by IHC or amplification by FISH. HER2 phenotype showed HER2 overexpression or amplification but were ER/PR negative. Women with LABC underwent dynamic [18F]-FDG and [15O]-water PET scans prior to NC. The FDG metabolic rate (MRFDG) and transport (FDG K1) parameters were calculated; blood flow (BF) was estimated from the water PET scan. Response to NC was determined from surgical specimens with pathologic complete response (pCR) defined as eradication of invasive tumor in the breast vs. other. Results: Of the tumors studied, 16 (31%) were TN, 30 (59%) were luminal, and 5 (10%) were HER2. pCR was observed in 4/16 (25%) TN tumors (95% CI: 0.10-0.50) compared to only 4/30 (13%) of luminal tumors (95% CI: 0.05-0.30) and 3/5 HER2 tumors. Linear regression of the association between PET parameters and phenotype (TN vs. luminal) found that TN was associated with higher MRFDG (p=0.007) and MRFDG/BF ratio (p=0.02), but not with BF (p=0.27). Only patients with low pre-therapy MRFDG/BF ratio (&amp;lt;35 umol/mL) achieved a pCR. Using this value as an ad-hoc cutoff, 4/7 (57%) of TN patients with low ratios had a pCR, while 0/9 with higher ratios had pCR. In contrast, only 4/21 (19%) of the luminal patients with low ratios had a pCR (one-sided mid-p=0.04 for TN vs. luminal pCR rate for patients with MRFDG/BF &amp;lt; 35 umol/mL). Discussion: These results demonstrate heterogeneity in breast tumor metabolism and perfusion as assessed by PET, and suggest a clinically relevant association between PET parameters and tumor phenotypes. The high MRFDG/BF ratio that predicts poor response to NC is more common in TN tumors; whereas in luminal or HER2 tumors, high MRFDG is generally matched with higher BF. Measurement of tumor metabolism and perfusion may identify a subset of tumors which are unlikely to respond to NC. Identification of such tumors may direct therapy toward those biologic targets most likely to overcome resistance. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6005.
National Cancer Act Reauthorized For Two Years
Authors: M. C. Knipmeyer
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article National Cancer Act Reauthorized For Two Years Get access Mary C. Knipmeyer, Ph.D. Mary C. Knipmeyer, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 20, 21 December 1988, Pages 1593–1594, https://doi.org/10.1093/jnci/80.20.1593 Published: 21 December 1988